Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders
- PMID: 35492718
- PMCID: PMC9051035
- DOI: 10.3389/fpsyt.2022.866052
Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders
Abstract
Emotional behavior, memory, and learning have been associated with alterations in the immune system in neuropsychiatric and neurodegenerative diseases. In recent years, several studies pointed out the involvement of the cannabinoid receptor 2 (CB2r) in the immune system and the regulation of inflammation. This receptor is widely distributed in different tissues and organs with higher expression in spleen and immune system cells. However, CB2r has also been detected in several brain areas and different brain cell types, such as neurons and glia. These findings suggest that CB2r may closely relate the immune system and the brain circuits regulating inflammation, mood, and cognitive functions. Therefore, we review the studies that may help elucidate the molecular bases of CB2r in regulating inflammation in different brain cells and its role in the pathophysiology of psychiatric and neurodegenerative disorders.
Keywords: Alzheimer’s disease; anxiety; cannabinoid receptor 2; depression; immunomodulation; inflammation; psychiatry.
Copyright © 2022 Morcuende, García-Gutiérrez, Tambaro, Nieto, Manzanares and Femenia.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders.Pharmacol Res. 2025 Mar;213:107657. doi: 10.1016/j.phrs.2025.107657. Epub 2025 Feb 18. Pharmacol Res. 2025. PMID: 39978657 Review.
-
Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies.Int J Mol Sci. 2022 May 25;23(11):5908. doi: 10.3390/ijms23115908. Int J Mol Sci. 2022. PMID: 35682586 Free PMC article. Review.
-
Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases.Eur J Pharmacol. 2021 Oct 15;909:174398. doi: 10.1016/j.ejphar.2021.174398. Epub 2021 Jul 29. Eur J Pharmacol. 2021. PMID: 34332924 Review.
-
The CB2 cannabinoid receptor as a therapeutic target in the central nervous system.Expert Opin Ther Targets. 2021 Aug;25(8):659-676. doi: 10.1080/14728222.2021.1971196. Epub 2021 Sep 23. Expert Opin Ther Targets. 2021. PMID: 34424117 Review.
-
Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.Molecules. 2022 Jan 21;27(3):702. doi: 10.3390/molecules27030702. Molecules. 2022. PMID: 35163968 Free PMC article.
Cited by
-
Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.Psychopharmacology (Berl). 2024 Oct;241(10):1939-1954. doi: 10.1007/s00213-024-06683-w. Epub 2024 Sep 12. Psychopharmacology (Berl). 2024. PMID: 39264450 Review.
-
Recent advances in anxiety disorders: Focus on animal models and pathological mechanisms.Animal Model Exp Med. 2023 Dec;6(6):559-572. doi: 10.1002/ame2.12360. Epub 2023 Nov 28. Animal Model Exp Med. 2023. PMID: 38013621 Free PMC article. Review.
-
Perturbation of 3D nuclear architecture, epigenomic aging and dysregulation, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 2-Metabolome, immunome, synaptome.Front Psychiatry. 2023 Oct 3;14:1182536. doi: 10.3389/fpsyt.2023.1182536. eCollection 2023. Front Psychiatry. 2023. PMID: 37854446 Free PMC article. Review.
-
Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression.J Neuroinflammation. 2024 Sep 8;21(1):219. doi: 10.1186/s12974-024-03213-5. J Neuroinflammation. 2024. PMID: 39245706 Free PMC article.
-
Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder.Neuromolecular Med. 2024 May 14;26(1):20. doi: 10.1007/s12017-024-08781-6. Neuromolecular Med. 2024. PMID: 38744725 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources